RA
XENE icon

Royce & Associates’s Xenon Pharmaceuticals XENE Stock Holding History

Royce & Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93M Buy
+65,032
New +$3.61M 0.03% 535

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Royce & Associates's XENE Position: Q2 2026 in Review

Royce & Associates opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 65,032 shares worth $3.93M. The stake represents 0.03% of the portfolio and ranks #535 among its holdings.

315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Royce & Associates held 65,032 shares of Xenon Pharmaceuticals worth $3.93M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Royce & Associates position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.03% of Royce & Associates's portfolio in Q2 2026, its #535 holding.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.